• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Mesenchymal Stromal Cell Therapy for Regenerative Medicine.

作者信息

Capilla-González Vivian, Herranz-Pérez Vicente, Sarabia-Estrada Rachel, Kadri Nadir, Moll Guido

机构信息

Department of Regeneration and Cell Therapy, Andalusian Center of Molecular Biology and Regenerative Medicine (CABIMER)-University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain.

Department of Cell Biology, Functional Biology and Physical Anthropology, School of Biological Sciences, University of Valencia, Valencia, Spain.

出版信息

Front Cell Neurosci. 2022 May 26;16:932281. doi: 10.3389/fncel.2022.932281. eCollection 2022.

DOI:10.3389/fncel.2022.932281
PMID:35693887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9179645/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503d/9179645/4eca53a93480/fncel-16-932281-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503d/9179645/4eca53a93480/fncel-16-932281-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503d/9179645/4eca53a93480/fncel-16-932281-g0001.jpg

相似文献

1
Editorial: Mesenchymal Stromal Cell Therapy for Regenerative Medicine.社论：用于再生医学的间充质基质细胞疗法
Front Cell Neurosci. 2022 May 26;16:932281. doi: 10.3389/fncel.2022.932281. eCollection 2022.
2
Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis.社论：下一代间充质干细胞治疗产品的制造、效力及作用机制分析
Front Immunol. 2023 Apr 21;14:1192636. doi: 10.3389/fimmu.2023.1192636. eCollection 2023.
3
Immunomodulation regulates mesenchymal stem cell-based bone regeneration.免疫调节可调控基于间充质干细胞的骨再生。
Oral Dis. 2014 Oct;20(7):633-6. doi: 10.1111/odi.12248. Epub 2014 May 7.
4
Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine.间质基质/干细胞的治疗特性：再生医学中细胞无细胞治疗需要细胞预刺激。
Int J Mol Sci. 2021 Jan 14;22(2):763. doi: 10.3390/ijms22020763.
5
TGF-β and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer.转化生长因子-β与间充质基质细胞在再生医学、自身免疫和癌症中的作用。
Cytokine Growth Factor Rev. 2018 Oct;43:25-37. doi: 10.1016/j.cytogfr.2018.06.002. Epub 2018 Jun 13.
6
Mesenchymal Stem/Progenitor Cells and Their Derivates in Tissue Regeneration.间质干细胞/祖细胞及其在组织再生中的衍生物。
Int J Mol Sci. 2022 Jun 15;23(12):6652. doi: 10.3390/ijms23126652.
7
Reparative and Regenerative Effects of Mesenchymal Stromal Cells-Promising Potential for Kidney Transplantation?间质基质细胞的修复和再生作用——对肾移植有潜在的促进作用？
Int J Mol Sci. 2019 Sep 18;20(18):4614. doi: 10.3390/ijms20184614.
8
Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy.间充质基质/干细胞作为糖尿病视网膜病变的潜在治疗方法。
Immunobiology. 2018 Dec;223(12):729-743. doi: 10.1016/j.imbio.2018.01.001. Epub 2018 Feb 15.
9
Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis.间充质基质细胞衍生的细胞外囊泡：再生和免疫调节作用及其在脓毒症中的潜在应用。
Cell Tissue Res. 2018 Oct;374(1):1-15. doi: 10.1007/s00441-018-2871-5. Epub 2018 Jun 28.
10
[Therapeutic potential of human mesenchymal stromal cells secreted components: a problem with standartization].人骨髓间充质干细胞分泌成分的治疗潜力：标准化问题
Biomed Khim. 2015 Nov-Dec;61(6):750-9. doi: 10.18097/PBMC20156106750.

引用本文的文献

1
Diverse-Origin Exosomes Therapeutic Strategies for Diabetic Wound Healing.不同来源外泌体治疗糖尿病伤口愈合的策略
Int J Nanomedicine. 2025 Jun 12;20:7375-7402. doi: 10.2147/IJN.S519379. eCollection 2025.
2
The Complementary Roles of Neurological and Musculoskeletal Physical Therapy and Regenerative Medicine: A Comprehensive Review.神经和肌肉骨骼物理疗法与再生医学的互补作用：全面综述。
Medicina (Kaunas). 2024 Jun 27;60(7):1062. doi: 10.3390/medicina60071062.
3
Regenerative and translational medicine in COPD: hype and hope.

本文引用的文献

1
Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products.改良 MSC 最小标准以最大化患者安全：呼吁采用组织因子和 MSC 产品血液相容性评估。
Stem Cells Transl Med. 2022 Mar 3;11(1):2-13. doi: 10.1093/stcltm/szab005.
2
Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.间充质基质细胞用于增强造血植入及治疗移植物抗宿主病、出血和急性呼吸窘迫综合征。
Front Immunol. 2022 Mar 18;13:839844. doi: 10.3389/fimmu.2022.839844. eCollection 2022.
3
COPD 中的再生和转化医学：炒作与希望。
Eur Respir Rev. 2023 Jul 26;32(169). doi: 10.1183/16000617.0223-2022. Print 2023 Sep 30.
4
Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis.社论：下一代间充质干细胞治疗产品的制造、效力及作用机制分析
Front Immunol. 2023 Apr 21;14:1192636. doi: 10.3389/fimmu.2023.1192636. eCollection 2023.
5
Immunological priming of mesenchymal stromal/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease engagement of PD-1 ligands.免疫原性的间充质基质/干细胞及其细胞外囊泡增强了它们在实验性移植物抗宿主病中的治疗益处 PD-1 配体的参与。
Front Immunol. 2023 Feb 16;14:1078551. doi: 10.3389/fimmu.2023.1078551. eCollection 2023.
6
Mesenchymal stem cells express epidermal markers in an reconstructed human skin model.间充质干细胞在重建的人类皮肤模型中表达表皮标志物。
Front Cell Dev Biol. 2023 Jan 12;10:1012637. doi: 10.3389/fcell.2022.1012637. eCollection 2022.
7
Adverse events, side effects and complications in mesenchymal stromal cell-based therapies.基于间充质基质细胞的疗法中的不良事件、副作用和并发症。
Stem Cell Investig. 2022 Nov 8;9:7. doi: 10.21037/sci-2022-025. eCollection 2022.
8
Mesenchymal Stem/Stromal Cells as a Therapeutic Tool in Cell-Based Therapy and Regenerative Medicine: An Introduction Expertise to the Topical Collection.间充质干细胞作为细胞治疗和再生医学中的治疗工具：专题集的专业知识介绍。
Cells. 2022 Oct 8;11(19):3158. doi: 10.3390/cells11193158.
9
Heterogeneity of In Vitro Expanded Mesenchymal Stromal Cells and Strategies to Improve Their Therapeutic Actions.体外扩增间充质基质细胞的异质性及改善其治疗作用的策略
Pharmaceutics. 2022 May 23;14(5):1112. doi: 10.3390/pharmaceutics14051112.
Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy.
间质基质细胞：潜在的微环境调节剂成为细胞治疗。
Cell Stem Cell. 2021 Oct 7;28(10):1708-1725. doi: 10.1016/j.stem.2021.09.006.
4
Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice.经鼻给药人骨髓间充质干细胞在幼年小鼠中的临床前安全性评估
Cancers (Basel). 2021 Mar 9;13(5):1169. doi: 10.3390/cancers13051169.
5
Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity.巨噬细胞在间充质基质细胞效力的枢纽：趋化因子协同作用的新兴作用。
Stem Cells. 2021 Sep;39(9):1145-1154. doi: 10.1002/stem.3380. Epub 2021 Apr 6.
6
Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition.影响临床疗效的间充质基质细胞变量：活力、适应性、给药途径和宿主易感性的影响。
Cytotherapy. 2021 May;23(5):368-372. doi: 10.1016/j.jcyt.2020.11.007. Epub 2021 Mar 11.
7
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.MSC 疗法治疗 COVID-19：患者凝血病、血栓预防、细胞产品质量和治疗安全性及疗效的输送方式的重要性。
Front Immunol. 2020 May 19;11:1091. doi: 10.3389/fimmu.2020.01091. eCollection 2020.
8
Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies.社论：间充质干细胞疗法的安全性、有效性及作用机制
Front Immunol. 2020 Feb 18;11:243. doi: 10.3389/fimmu.2020.00243. eCollection 2020.
9
Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy.间充质干细胞在癌症治疗中的治疗潜力
Front Bioeng Biotechnol. 2020 Feb 5;8:43. doi: 10.3389/fbioe.2020.00043. eCollection 2020.
10
Mesenchymal stem cell perspective: cell biology to clinical progress.间充质干细胞展望：从细胞生物学到临床进展
NPJ Regen Med. 2019 Dec 2;4:22. doi: 10.1038/s41536-019-0083-6. eCollection 2019.